The additional historical financial information contained in the registration statement includes profit data by reporting segment which is required under US accounting rules, and quarterly results information. This press release does not constitute an offer for securities, which will only be made by means of a prospectus. As reported in Nycomed Amersham's interim results for the six months to 30 June 2000, Amersham Pharmacia Biotech's operating profit, before integration costs and goodwill amortisation, amounted to 29m. The segments given are for reporting purposes only and should not be regarded as separate businesses. After flotation, Amersham Pharmacia Biotech will report financial results in accordance with US GAAP on a quarterly basis.
Profits exhibit significant seasonal variation reflecting customer purchase patterns.
Operating profits, before integration costs and goodwill amortisation, under UK GAAP in the first and second quarters of 2000 amounted to 6m and 23m respectively. The figures for the full year 1999 were 6m, 23m, 11m and 42m respectively, giving the previously reported total of 82m.